contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


expres2ion-biotechnologies-expres2ion-to-present-in-upcoming-investor-and-scientific-events-1

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

ExpreS2ion is a Danish-based biotech company listed in Sweden. The company develops a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer through the use of its non-viral cell-based expression system, ExpreS2, which is recognized for handling protein challenges. ExpreS2ion has developed Expres2, which is a technology platform for efficient and fast non-clinical development and production of complex proteins for new vaccines and diagnostics.

The company’s current primary product is the corona vaccine candidate, ABNCoV2 in phase 2, co-developed with its partner, AdaptVac of which ExpreS2ion owns 34%. The vaccine candidate has been licensed to Bavarian Nordic has global commercialization rights and responsibility for further clinical development of the vaccine and is expected to initiate phase 3 testing for the product candidate in the first half of 2022.

ExpreS2ion Biotech Holding

Hørsholm, Denmark, 31 October2024 - ExpreS2ion Biotech Holding AB's subsidiary ExpreS2ion Biotechnologies ApS ("ExpreS2ion") will participate in upcoming investor and scientific events, including...

<div class="abstract">Hørsholm, Denmark, 31 October2024 - ExpreS2ion Biotech Holding AB's subsidiary ExpreS2ion Biotechnologies ApS ("ExpreS2ion") will participate in upcoming investor and scientific events, including BIO-Europe, the Protein &amp; Antibody Engineering Summit Europe, a 2024 Third Quarter Results Webinar, and the LSX Investival Showcase.</div>By attending relevant industry and investor events, the company aims to increase the awareness of its technology platform and its exciting development pipeline. More information on each event and how to register is found below and on the Company's website&nbsp;(<a href="https://expres2ionbio.com/media/events/">https://expres2ionbio.com/media/events/</a>) and via the links below.4-6 November 2024 | BIO-Europe 2024 Stockholm, Sweden CEO Bent Frandsen will represent ExpreS2ion at BIO-Europe in Stockholm, 4 - 6 November. To pre-arrange a meeting, please contact us via email on&nbsp;info@expreS2ionbio.com.More information is available on BIO-Europe's&nbsp;website&nbsp;(<a href="https://informaconnect.com/bioeurope/">https://informaconnect.com/bioeurope/</a>).5-7 November 2024 | Protein &amp; Antibody Summit Europe Barcelona, Spain PEGS Europe is the largest protein &amp; antibody engineering event in Europe, and in 2024 includes an entire stream devoted to Oncology. ExpreS2ion's SVP of R&amp;D and Technology, Max Soegaard, will represent the company. For more information, please visit the event&nbsp;website&nbsp;(<a href="https://www.pegsummiteurope.com/">https://www.pegsummiteurope.com/</a>).14 November 2024 | Presentation of 2024 Third Quarter Results 11:00 - 11:30 | Virtual ExpreS2ion CEO Bent Frandsen and CFO Keith Alexander will present 2024 third quarter interim results and take questions from investors. Please register via the&nbsp;ExpreS2ion landing page&nbsp;(<a href="https://www.inderes.dk/videos/expres2ion-biotechnologies-presentation-of-q3-2024">https://www.inderes.dk/videos/expres2ion-biotechnologies-presentation-of-q3-2024</a>)&nbsp;on the Inderes website in the weeks leading up to the webcast.18 November 2024 | LSX Investival Showcase London, UK The Investival Showcase is a Biotech, Healthtech and Medtech networking event for startup, growth stage and publicly listed companies. CFO Keith Alexander will participate. To schedule a meeting, please contact us via investor@expres2ionbio.com.More information is available on the&nbsp;LSX website&nbsp;(<a href="https://informaconnect.com/investival-showcase/">https://informaconnect.com/investival-showcase/</a>).Certified Adviser Svensk Kapitalmarknadsgranskning AB

ExpreS2ion Biotechnologies: ExpreS2ion to present in upcoming investor and scientific events

Wall Streetin arvostustasoihin verrattuna Eurooppakin näyttää nyt houkuttelevalta

Federal Reserven korkopäätös: Kiire loppui tähän

Drug development investment: Value creation through M&As and licensing agreements

EKP:n korkopäätös: Keskuspankki ilman rajoitteita

Euroalueen ostopäälliköt: Onks sen jälkeen vielä mäki?

Stay up to date with our newsletter